[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Na Homolce Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100472974","early-aortic-valve-surgery-versus-watchful-waiting-strategy-in-severe-asymptomatic-aortic-regurgitation-100472974",false,"NCT05438862","Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation","Early Aortic Valve Surgery Versus Watchful Waiting Strategy in Severe Asymptomatic Aortic Regurgitation","ELEANOR","Inclusion Criteria:\n\n* Chronic asymptomatic aortic regurgitation grade 3 (moderate to severe) and grade 4 (severe)\n* No indication for the surgical treatment at the time of enrolment\n* LV ejection fraction \\>50%\n* Absence of more than mild-to-moderate concomitant valve disease or complex congenital heart disease\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Clearance Creatinine \\\u003C30 mL\u002Fmin\n* Contraindication for magnetic resonance (implanted active device, ferromagnetic implant incompatible with magnetic resonance scanner, cerebral aneurysm clip, metallic fragment in the eye or near sensitive tissue)\n* Pregnancy\n* Permanent atrial fibrillation.","ALL","18 Years",{"count":20,"type":21},217,"ESTIMATED","INTERVENTIONAL",[24],"NA","The optimal timing of surgical intervention in asymptomatic patients with severe aortic regurgitation remains controversial. As per cardiac magnetic resonance assessment, early surgical treatment will be compared with conventional guideline-based strategy in asymptomatic patients with severe aortic regurgitation.",[27],"Aortic Valve Regurgitation",[29,30,31,32],"aortic regurgitation","cardiac magnetic resonance","echocardiography","early surgical intervention","RECRUITING","2026-02-13",{"date":36,"type":37},"2026-02-17","ACTUAL",{"date":39,"type":37},"2022-09-01",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Na Homolce Hospital","OTHER",8,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100591683","new-onset-of-arrhythmia-after-patent-foramen-ovale-pfo-closure-100591683","NCT06983613","New Onset of Arrhythmia After Patent Foramen Ovale (PFO) Closure","New Onset of Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure - Na Homolce Hospital","Inclusion Criteria:\n\n* Indication for percutaneous closure of patent foramen ovale due to stroke, confirmed through an interdisciplinary meeting between cardiologists and neurologists, in accordance with current guidelines.\n* Age \\> 18 years.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Patients with a known history of atrial fibrillation, atrial flutter, or atrial tachycardia.",{"count":54,"type":21},150,"OBSERVATIONAL","Embolic stroke of undetermined source (ESUS) accounts for approximately 25% of all ischemic strokes, with patent foramen ovale (PFO) considered a major mechanism behind ESUS. When specific anatomic criteria are met, transcatheter PFO occlusion is regarded as the gold standard for secondary stroke prevention.\n\nHowever, previous studies have shown that percutaneous PFO closure may increase the risk of new-onset atrial fibrillation and atrial flutter (AF), arrhythmias that elevate the risk of embolic stroke. This raises concerns about performing PFO closure. Indeed, the most common clinically significant complication after catheter-based PFO closure is AF. Available data indicates that AF typically occurs in the early period following occluder implantation, with peak incidence around the 14th day post-closure, followed by a decline after the 45th day. Although AF is considered the most frequent adverse complication after percutaneous PFO occlusion, its incidence remains relatively low, ranging from 3% to 7.4%, depending on the method used for arrhythmia screening, though this remains unclear.\n\nIn this study, investigators will prospectively monitor patients who have experienced ESUS and are indicated for PFO closure. They will be screened for the occurrence of AF following percutaneous PFO closure using a 3-week ECG Holter monitor (from day 7 to day 28 post-closure) and again 1 week (one year post-closure) after the procedure. The study aims to determine the true incidence of new-onset AF following catheter-based PFO occlusion and to identify the risk factors associated with its development.",[58],"Cardiovascular Diseases","2025-05-14",{"date":61,"type":37},"2025-05-21",{"date":63,"type":37},"2025-01-15",{"date":65,"type":21},"2028-12-31",{"name":43,"class":44},""]